Mixed reactions among HCPs as lecanemab and donanemab secure FDA approval for Alzheimer's treatment

Last month, the FDA granted approval to Eli Lilly’s donanemab - or Kisunla - for the treatment of Alzheimer’s disease. Its approval was based on the treatment demonstrating what the FDA described as a “statistically significant reduction in clinical decline on the integrated Alzheimer's Disease Rating Scale (iADRS) compared to placebo”. Anne White, Eli Lilly’s executive vice president, said that the amyloid plaque-targeting therapy had shown “very meaningful results for people with early symptomatic Alzheimer's disease.”